Intracoronary infusions of activated complement C5a result in myocardial ischemia, contractile dysfunction, and leukocyte accumulation. The (500 ng) were assessed before and after 1) LTDJLTE4 receptor blockade with leukotriene receptor blocker LY171883 (10 mg/kg i.v.) (n =5), 2) thromboxane AJprostaglandin H2 receptor blockade with thromboxane receptor blocker BM13505 (2 mg/kg i.v.) (n=5), and 3) combined thromboxane and leukotriene receptor blockade (n =5). In the absence of receptor blockade, intracoronary C5a decreased coronary flow (50-60%) and regional segment function (60-70%) compared with the preinfusion levels. This was accompanied by a fall in coronary venous blood leukocyte levels by 5-6x 106 cells/ml in the absence of alterations in arterial blood leukocyte count. Intracoronary injections of LTD4, LTC4, or U46619 also resulted in prompt decreases in coronary blood flow (50-60%) and segment function (70-80%1) from preinfusion levels.
(500 ng) were assessed before and after 1) LTDJLTE4 receptor blockade with leukotriene receptor blocker LY171883 (10 mg/kg i.v.) (n =5), 2) thromboxane AJprostaglandin H2 receptor blockade with thromboxane receptor blocker BM13505 (2 mg/kg i.v.) (n=5), and 3) combined thromboxane and leukotriene receptor blockade (n =5). In the absence of receptor blockade, intracoronary C5a decreased coronary flow (50-60%) and regional segment function (60-70%) compared with the preinfusion levels. This was accompanied by a fall in coronary venous blood leukocyte levels by 5- T he serum complement pathway is an essential component of the mammalian host defense system and participates in a wide variety of pathophysiological processes including autoimmunity, hypersensitivity, and inflammation. There is increasing evidence that the complement system is involved in the inflammatory response resulting from acute myocardial ischemia, which is characterized by the local infiltration of leukocytes.1-5 The extent of myocardial infarction due to coronary occlusion is reduced by the prior depletion of complement,6,7 and components of the complement pathway are found in ischemic myocardium and colocalize with areas of granulocyte accumulation.5,6,8 Activation of the complement cascade by either the classical or alternative pathway results in the generation of the biologically active polypeptide fragments, the anaphylatoxins C3a and C5a. The action of these molecules, particularly C5a, on specific membrane receptors that are present on a wide variety of cell types, including smooth muscle cells, mast cells, and blood cells (i.e., leukocytes), can result in the release of secondary mediators, including kinins, histamine, thromboxane A2, and leukotrienes, with profound effects on vascular permeability and vessel caliber. Intracoronary infusions of C5a produce transient increases in coronary vascular resistance, contractile dysfunction, and a myocardial accumulation of leukocytes.9 This myocardial response is associated with sixfold to eightfold increases in coronary venous levels of thromboxane B2,1' which is the breakdown product of thromboxane A2, a potent coronary vasoconstrictor. However, it is not clear whether the C5a-induced generation of thromboxane A2 is directly responsible for the observed decreases in coronary blood flow, since cyclooxygenase blockade failed to blunt the ischemic response.10 Furthermore, in the pulmonary vascular bed and the isolated heart, activated complement can result in an enhanced generation of the major components of slow-reacting substance of anaphylaxis (SRS-A), the 5-lipoxygenase peptidoleukotrienes (LTC4, LTD4, and LTE4)."11"2 These leukotrienes are known to have potent coronary vasoconstrictor effects. '3,"4 The goal of the present study was to determine the contribution of thromboxane A2 and the peptidoleukotrienes, LTC4, LTD4, and LTE4, to the decreases in coronary blood flow and contractile dysfunction induced by activated complement C5a.
Materials and Methods General Preparation
Domestic pigs (25-30 kg) of either sex were premedicated with ketamine (2.5 mg/kg i.m.) and anesthetized 10-15 minutes later, initially with sodium thiamylal (10-15 mg/kg i.v.) followed by a-chloralose (100 mg/kg i.v.) and morphine sulfate (30 mg/hr s.c.) After intubation with a cuffed endotracheal tube, animals were ventilated with a positive-pressure respirator (Harvard Apparatus, South Natick, Massachusetts) with an end-expiratory pressure of 3-5 cm H20. Arterial blood was regularly sampled for determination of P02, Pco2, or pH (Corning Medical, Medfield, Massachusetts). Blood gas values were kept within the physiological range by adjustments of the ventilatory rate and oxygen supplementation. The anesthetic level was maintained with bolus doses of a-chloralose (250-500 mg i.v.). Animal core temperature (rectal) was monitored (Yellow Springs Instrument, Yellow Springs, Ohio) and maintained at 370 C with a circulating-water heating pad.
Aortic blood pressure was measured with a strain gauge manometer (Statham P23Db, Gould, Oxnard, California) through a polyethylene catheter placed into the aorta via the right femoral artery. Left ventricular (LV) pressure was obtained using a catheter-tip manometer (model 7F, Millar, Houston, Texas) inserted into the left ventricle via the right carotid artery. This signal was recorded at full scale and high gain for determination of peak LV pressure (LVP) and LV end-diastolic pressure (LVEDP) and differentiated to obtain LV dP/dt.
The heart was exposed through a midline sternotomy and left thoracotomy in the fourth intercostal space and suspended in a pericardial cradle. A section of the left anterior descending coronary artery (LAD) just distal to the bifurcation of the left main artery was dissected free from underlying tissue for cannulation. Anticoagulation was achieved with sodium heparin (500 units/kg i.v.) and maintained by hourly supplemental doses of 250 units/kg. Two extracorporeal circuits were used and are described below ( Figure 1 ).
LAD Perfusion
The LAD was cannulated just distal to the left main bifurcation and perfused from the left common carotid artery, using a silastic and polyethylene extracorporeal tubing circuit. Coronary artery perfusion pressure was measured just proximal to the cannula tip through a side arm (Statham 23dB, Gould). Coronary Four series of experiments were performed: 1) In the "leukotriene receptor blockade" group (n=5), control responses to separate intracoronary challenges of LTC4 (1 ,g), LTD4 (1 gg), and CSa (500 ng) were obtained. The leukotriene receptor blocker LY171883 (10 mg/kg in saline) was administered intravenously, and the injection protocol was repeated with C5a given first, followed by the LTC4 and LTD4 injections to confirm receptor blockade. 2) In the "thromboxane receptor blockade" group (n=5), responses to separate intracoronary challenges of LTD4 (1 jug), thromboxane analog U46619 (7.5 ,g), and C5a (500 ng) were obtained before and after thromboxane receptor blockade with BM13505 (2 mg/kg i.v. in saline). After blockade, C5a was given first, followed by the LTD4 and U46619 challenges. 3) In the "combined receptor blockade" group (n =5), responses to LTC4 or LTD4 (1 gg), U46619 (7.5 gg), and C5a (500 ng)
were obtained under control conditions. After 30 minutes, leukotriene receptor blockade was achieved with LY171883 (10 mg/kg i.v.), and a second C5a (500 ng) injection was given. After a 30-minute interval, BM13505 (2 mg/kg i.v.) was administered, and the response to a third injection of C5a (500 ng) was tested. Ten minutes after this last injection, combined thromboxane and leukotriene receptor blockade was confirmed by separate challenges with leukotriene LTC4 or LTD4 (1 ,ug) and U46619 (7.5 ,Lg). 4) In the "time control" group (n=4), the response to three injections of C5a (500 ng) given 30 minutes apart without receptor blockade was assessed to rule out preparation degradation and tachyphylaxis to C5a.
Experimental Protocol
The protocol for an experimental run consisted of a prestimulus period, a 1-minute drug injection period, and a 5-minute recovery period. Coronary venous blood samples were obtained before injection, at 30 and 60 seconds during injection, and 15, 30, 45, 60, and 120 seconds after injection. Arterial blood samples were obtained before injection, at 60 seconds during injection, and 60 and 120 seconds after injection. The C5a injections in the leukotriene receptor blockade group and the thromboxane receptor blockade group occurred 60 minutes apart, with all blocking agents administered approximately 10-15 minutes before the second C5a challenge. This 60-minute interval for C5a challenges was determined in a separate study10 to be sufficient to avoid problems with tachyphylaxis known to be present with repeated exposure to C5a. In the combined blockade group, the interval between C5a challenges was 30 minutes. Validation of this injection interval is presented in the "time control" group results.
Aortic pressure, LVP, LVEDP, LV dP/dt, ultrasonic segment lengths, and mean coronary blood flow were recorded on an eight-channel oscillographic recorder (Gould-Brush, Cleveland, Ohio). All measurements were obtained with respiration suspended at end expiration to avoid respiratory fluctuations in segment lengths. Data Analysis Data were read from analog records at the control time point, 15 -second intervals during the injection period, 1 minute after injection, and every 30 seconds for 4 minutes thereafter. At each time point, mean coronary blood flow, systolic and diastolic aortic blood pressure, peak LVP, LVEDP, LV dP/dt, and segment lengths were read. Data from three to four consecutive cardiac cycles were averaged for each experimental time point. Regional segment lengths in millimeters were determined at end diastole and end systole. The end-diastolic length (EDL) was measured after the A wave, at the time of the sharp upsweep in the high-gain LVP signal. The end-systolic length (ESL) was defined at the point 20 msec before peak negative dP/dt. Regional myocardial function was calculated as percent segment shortening (%SS) defined as (EDL-ESL/EDL) x 100.
The study was designed to have each animal serve as its own control. The preinjection control value for an individual pig for each experimental condition was taken just before the onset of the C5a injection period. For the coronary blood flow and regional function data, all measurements are expressed as a percent of this control value. The averages of these values for all pigs in each experimental group are shown in the figures. The standard errors of the mean given in the figures and text were derived from data sets containing one value from each pig studied in any given experimental group (n-1 degrees of freedom).
Statistical analyses of the difference between the preinjection control point and the response at selected points during and after the injection period were made by a repeated-measures analysis of variance. A paired t test with Bonferroni's correction was used to compare the statistical differences in the responses after each intervention in all experimental groups and is indicated on the figures.
Results

Leukotriene Receptor Blockade Group
Average values for five pigs that were subjected to the leukotriene blockade protocol are shown in Figures 2 and 3 . Before leukotriene receptor blockade, the intracoronary injection of LTC4 (1 ,ug) resulted in a marked decrease in coronary blood flow to a nadir of 41.3+8.1% of the preinjection level of 0.89±0.10 ml/min/g (p<0.01) (Figure 2 ). This was accompanied by a significant fall (p<0.01) in regional contractile function in the LAD perfusion area to a minimum value of 16.6±9.1% of the preinjection %SS level of 23.4±1.5% of the EDL (11.7±1.0 mm). Changes in segment shortening in the circumflex region were minor, slightly increasing by less than 10% during and after the LTC4 injection. Heart rate (100±9 beats/min), peak LVP (101.8±5.7 mm Hg), and LVEDP (3.3±0.4 mm Hg) did not significantly change during the injection period. After leukotriene receptor blockade with LY171883 (10 mg/kg), the LTC4-induced fall in coronary blood flow and LAD regional function were abolished ( Figure 2 ). This occurred in the absence of major effects of LY171883 on either resting coronary blood flow (0.82±0.09 ml/min/g) or segment function (%SS=19.9±1.7% of EDL). Also, heart rate (95±5.2 beats/min), LVP (100.8±6.1 mm Hg), and LVEDP (3.7±0.9 mm Hg) values were similar to those before blockade. Before receptor blockade, the intracoronary injection of LTD4 (1 gg) resulted in decreases in coronary blood flow and regional segment function similar to that found with LTC4. Coronary flow fell to a nadir of 47.4±9.1% of the preinjection value of (0.85±0.10 ml/min/g) (p<0.01) accompanied by a reduction in LAD segment shortening to 22 into the injection period (p<0.01) (Figure 3 [LTD4 i. (Figure 8 ). An effective coronary vascular leukotriene and thromboxane receptor blockade was still present after the last CSa injection. At this time, the injection of leukotriene (LTC4 or LTD4) was ineffective in altering coronary flow and LAD segment shortening with levels remaining within 5% of preinfusion values (coronary flow, 0.71±0.11 ml/min/g; %SS, 25.1±2.3% of EDL) over the experimental run. This was in contrast to the initial leukotriene injection that markedly lowered coronary flow to 42.6±6.1% of preinjection (0.80±0.15 ml/min/g) and LAD segment shortening to 51.2±9.5% of the preinjection %SS (27.2±2.6% of EDL). Similarly, the intracoronary challenge with U46619 after the last C5a injection was without major effect on coronary flow or LAD segment function, which remained within 7% of preinfusion levels. This was in contrast to the initial injection of U46619, which markedly decreased coronary flow and segment function (26±6.7% and 50.8±14%, respectively, of preinjection levels). Heart rates (82±10 vs. 83±10 beats/min), peak LVPs (89±6 vs. 94+7 mm Hg), and LVEDPs (4.2±1.1 vs. 4.4±0.8 mm Hg) were similar after the combined blockade Compared with the control experimental run.
Time Control Group
There was no detectable effect of time or tachyphylaxis to three injections of C5a given 30 minutes apart (n=4). In these animals, the first injection of C5a resulted in a decrease in coronary blood flow to a value of 62.3±9.9% of the preinfusion level (0.87±0.10 ml/min/g). With the second injection, coronary flow fell to 54.6±11.8% of the preinfusion level (0.93±0.13 ml/min/g). The third injection of C5a decreased coronary flow to 62.0±16.0% of the preinfusion level (0.97±0.17 ml/min/g), not different (p>0.10) compared with the first injection response. Similar results were obtained in LAD %SS, which fell to 62.3 ± 9.9% of the preinjection level during the first C5a injection and to 67.8+11.7% of the preinjection level during the third injection of C5a. There was also no diminution in the C5a-induced myocardial extraction of leukocytes, which was 7.6±1.9 x103 cells/,ul with the first injection and 7.4±1.8x103 cells/gl with the third injection.
Discussion
These data demonstrate that the generation of thromboxane A2 and the peptidoleukotrienes (LTC4, LTD4, or LTE4) contribute to the coronary vasoconstriction and myocardial ischemia resulting from intracoronary infusions of C5a. Pharmacological blockade of either the prostaglandin H2/thromboxane A2 receptor with BM13505 ( Figure 6 ) or the LTD4/ LTE4 receptor with LY171883 (Figure 3 ) attenuated the C5a-induced decrease in coronary blood flow and fall in contractile function. The residual myocardial response to C5a after the combined receptor blockade was less than 5% of the preinjection value ( Figure 7 ). This blunting of the decrease in coronary blood flow in response to C5a occurred at constant coronary perfusion pressure and in the absence of major changes in heart rate and LVP. The attenuation of the response to C5a could not be explained by by guest on April 13, 2017 http://circres.ahajournals.org/ Downloaded from preparation degradation over time or tachyphylaxis to C5a. The myocardial accumulation of leukocytes associated with the intracoronary infusion of C5a was not influenced by thromboxane and/or leukotriene receptor blockade.
The majority of the information on the effects of activated complement on vascular resistance has been obtained in the pulmonary circulation. Several studies have now shown that systemic activation of the complement cascade occurring with the protamine reversal of heparin or the infusion of complement-activated plasma results in a characteristic pulmonary hypertension, pulmonary leukostasis, and extravasation of plasma proteins. [17] [18] [19] [20] [21] [22] [23] It is now apparent that many of these changes are secondary to the generation of metabolites of arachidonic acid from both the cyclooxygenase and 5-lipoxygenase pathways. The increase in pulmonary vascular resistance is associated with marked increases in plasma thromboxane B2 levels20,22,24 and can be attenuated with cyclooxygenase blockade20,23,24 or with scavengers of hydrogen peroxide. 24 The contribution of components of SRS-A, the 5 -lipoxygenase peptidoleukotrienes (LTC4, LTD4, and LTE4), to C5a-mediated pulmonary effects has also been suggested.11,25 Incubation of lung fragments with activated complement was shown to release an LTD4-like substance with a chromatographic behavior identical to LTD4.11 In addition, this substance induced smooth muscle contraction in a bioassay model, which was blocked by the leukotriene receptor blocker FPL55712. 11 The role of thromboxane A2 and the peptidoleukotrienes in the C5a-induced vascular resistance changes in the myocardial circulation is not as well understood. It has recently been demonstrated that the myocardial ischemia and contractile dysfunction induced by intracoronary C5a is accompanied by an enhanced production of thromboxane A2 as reflected by thromboxane B2 levels in coronary venous blood.10 However, cyclooxygenase blockade with aspirin or indomethacin was without major effect.10 In the present study, blockade of the prostaglandin HJ thromboxane A2 receptor with BM13505 ( Figure 6 ) attenuated the C5a-induced decrease in coronary blood flow and contractile function. The degree of receptor blockade achieved with the 2 mg/kg dose of BM13505 was sufficient to virtually eliminate the myocardial response to the thromboxane A2 agonist U46619 ( Figure 5 ). It is unlikely that the attenuation of the C5a response was due to a nonspecific action of the drug on the coronary vascular smooth muscle since the decrease in coronary blood flow elicited by a different receptor-mediated coronary vasoconstrictor (LTD4 or LTC4) was not attenuated by the administration of BM13505 (Figure 4 ). This drug also had no effect on the C5a-induced myocardial leukocyte extraction, suggesting that the drug does not alter the interaction of C5a with its leukocyte membrane receptor, although this possibility cannot be completely excluded. Thus, these data demonstrate that the enhanced production of thromboxane A2 known to occur in response to C5a10 does contribute to the increased coronary vascular resistance.
In a previous study,10 the administration of the cyclooxygenase inhibitors, aspirin or indomethacin, eliminated the production of thromboxane but did not significantly attenuate the myocardial response to C5a, in contrast to the effect of thromboxane receptor blockade demonstrated here. The reason for these apparent contradictory results are presently unclear. Several possibilities seem reasonable: 1) Cyclooxygenase-dependent coronary vasodilators such as prostaglandin 12 might be produced in addition to thromboxane A2. Thus, the effect of cyclooxygenase inhibition would be confounded by the elimination of both a coronary vasoconstrictor and vasodilator, resulting in no net change from the control response. This masking influence would not occur with the blockade of the receptor for the vasoconstrictive component alone (i.e., with BM13505). 2) Cyclooxygenase inhibition could result in the greater production of another coronary vasoconstrictor (i.e., peptidoleukotrienes), offsetting the loss of the thromboxane A2 generation. The known coronary vasoconstrictor properties of the leukotrienes13,14 (Figure 2) , the parallel nature of their generation from arachidonic acid, and the present data ( Figures  3 and 7) indicating their action during the C5a injection, are consistent with this possibility. There is experimental data from in vitro preparations demonstrating that "shunting" of arachidonic acid metabolism to the enhanced generation of the peptidoleukotrienes via the 5-lipoxygenase pathway can occur on cyclooxygenase blockade.12,25-27 The mechanism for this shunting effect is unclear, but a simple redirection of substrate by cyclooxygenase blockade to the 5-lipoxygenase pathway is unlikely.26 Evaluation of this shunting mechanism in the present in vivo model of intracoronary C5a injections, which uses measurements of coronary venous leukotriene levels before and after cyclooxygenase blockade, although attractive, is hindered by the short half-lives of these compounds in blood.
In the present study, the blockade of the LTD4/ LTE4 receptor with LY171883 also attenuated the C5a-induced fall in coronary blood flow and systolic shortening; thus, the involvement of these peptidoleukotrienes is indicated in this response (Figure 3) . The degree of receptor blockade was sufficient to eliminate the coronary vasoconstriction in response to intracoronary challenges with either LTC4 or LTD4 (Figure 2 ). This receptor blocker has been shown to be selective for the LTD4/LTE4 receptor. 27 The inhibitory effect of LY171883 on the coronary vasoconstriction to LTC4 is likely due to the rapid conversion of exogenous LTC4 to LTD4 in blood and its subsequent action on the LTDJLTE4 receptor. Although there is some evidence for the existence of a separate LTC4 receptor that can be demonstrated in vitro27 or in the presence of agents that inhibit the by guest on April 13, 2017 http://circres.ahajournals.org/ Downloaded from conversion of LTC4 to LTD4 via the y-glutamyltransferase enzyme, its physiological significance is unknown. However, our data suggest that a major role for an LTC4 receptor-mediated vasoconstriction in porcine coronary arteries in the present model is unlikely, since combined thromboxane A2 and LTD4/ LTE4 receptor blockade eliminated most of the C5a-induced vasoconstriction with little residual effect remaining (Figure 7) .
It should be noted that the attenuation of the C5a-induced myocardial ischemia by leukotriene and/or thromboxane receptor blockade occurred in the absence of significant changes in the magnitude of the myocardial leukocyte accumulation (Figure 8 ). In addition, it has been previously shown that similar or even greater degrees of leukocyte accumulation can result from intracoronary infusions of leukotriene B4 without detectable changes in coronary flow or contractile function. 28 Collectively, these data suggest that, in this model, capillary plugging by leukocytes, in itself, is not responsible for the fall in myocardial perfusion and that coronary vasoconstriction via the production of eicosanoids is more important. However, the presence of blood leukocytes and/or platelets does appear to play a role in the C5a-induced vasoconstriction since their removal greatly attenuates the response.29 The C5a-induced production of eicosanoids may not be entirely dependent on the presence of blood cellular components. There is evidence that activated complement C3a can result in the release of histamine and cyclooxygenase metabolites in Langendorff isolated hearts perfused with crystalloid solution'1 in the absence of blood cells.
The specific cells that are the source of the C5a-liberated eicosanoids in this model are not known. Activated blood leukocytes are capable of producing both cyclooxygenase30 and 5-lipoxygenase products. [31] [32] In addition, the release of thromboxane from activated platelets is a well-recognized phenomenon. The role of platelets in the myocardial response to C5a in the present model is unclear. Porcine C5a has been shown to directly activate guinea pig platelets.33'34 However, because the porcine C5a used in the present study does not aggregate platelets isolated from farm pigs (unpublished results), this effect may be species dependent. A direct effect of C5a on platelets may not be necessary. An interaction of activated polymorphonuclear leukocytes with platelets as a component of the inflammatory response has been previously described. Platelet deposition in inflamed tissue is greatly attenuated by prior depletion of circulating neutrophils. 35, 36 In the present model, blood cellular components alone do not appear to be solely responsible for the increase in coronary venous blood thromboxane B2 levels seen with C5a. Incubation of whole blood with C5a does not result in a significant increase in thromboxane A2 levels. 10 Thus, the release of these eicosanoids may require the interaction of activated leukocytes and/or platelets with the vascular wall. It is also possible that the vascular wall itself is a source of the eicosanoids released in the present model. Although vascular endothelium is not normally considered a rich source of thromboxane, endothelial cells can generate measurable amounts of thromboxane A2.37-39 Furthermore, the production of LTC4 from endothelial cells via an intercellular transfer of leukotriene A4 from polymorphonuclear leukocytes has also been described. 40 Oxygen derived free-radical species generated from complement C5a-activated leukocytes41 and their action on the vascular endothelium or platelets may be an important component of the C5a response. It has been reported that the enhanced arachidonic acid metabolism occurring in the pulmonary vascular bed with complement activation is dependent on the production of oxygen free-radical species or H202.23 Furthermore, in the buffer-perfused lung, free-radical generation with xanthine and xanthine oxidase also results in thromboxane release. 42 In an isolated heart preparation, activation of neutrophils with phorbol ester in buffer resulted in coronary vasoconstriction and contractile dysfunction that could be attenuated with free-radical scavengers43; thus, polymorphonuclear leukocytes may be the source of these free radicals. The C5a activation of leukocytes, their adherence to the vascular wall, the concomitant production of free radicals, and freeradical-dependent mobilization of membrane arachidonic acid may all be necessary components of the myocardial response to C5a.
Several studies have indicated that the generation of arachidonic acid metabolites, especially the leukotrienes, contributes to the extent of myocardial injury that results from acute coronary occlusion.24"45 The mechanism by which these products are formed and subsequently promote further myocardial injury is not clear. However, our data suggest that the production of lipoxygenase-and cyclooxygenase-derived coronary vasoconstrictors secondary to leukocyte activation may be involved.
In conclusion, the coronary vasoconstriction and contractile dysfunction in response to the intracoronary infusion of activated complement C5a is mediated in part by thromboxane A2 and the 5-lipoxygenase peptidoleukotrienes.
